New Jersey Senate Bill S93

New Jersey 2024-2025 Regular Session

• Introduced: 1/9/24
• Refer: 1/9/24

Caption

Requires hospital laboratories and bio-analytical or clinical laboratories to offer test for hepatitis C to certain individuals; authorizes certain laboratories to perform rapid tests for hepatitis C.

Impact

The bill is framed as a proactive public health measure aimed at identifying undetected cases of hepatitis C among the specified age group, as those individuals constitute approximately 75% of all chronic hepatitis C infections in the U.S. and are five times more likely to be infected. By facilitating screening at points of care and adhering to CDC recommendations, the legislation is positioned to promote timely diagnosis and treatment, improve health outcomes, and ultimately reduce healthcare costs associated with liver disease. The bill also stipulates that health benefits carriers must reimburse labs at in-network rates, preventing out-of-pocket expenses for patients undergoing screenings, thereby eliminating barriers to necessary testing.

Summary

Senate Bill S93 aims to enhance the screening process for hepatitis C in New Jersey, particularly targeting individuals born between January 1, 1945 and December 31, 1965, who are at a higher risk for the infection. The bill mandates that hospitals and bio-analytical or clinical laboratories provide these individuals with a verbal and written statement about the Center for Disease Control and Prevention (CDC) policy on hepatitis C screening upon their registration for laboratory services. Furthermore, it requires that if a patient consents, a hepatitis C screening test must be performed, with results transmitted to the referring health care provider.

Contention

While the bill is largely framed as a positive health initiative, it could also face scrutiny regarding privacy and testing requirements. Some health professionals might raise concerns over the practicality of retroactive testing protocols and potential implications for patients previously screened. Moreover, stakeholders in the healthcare sector might debate the financial burdens placed on health insurance plans and laboratories due to the mandates outlined in the bill. The commissioner is tasked with evaluating the law's impacts and reporting on screening numbers and follow-up care efficiency, providing a basis for future legislative adjustments.